Table 2.

Guidelines on screening for hepatitis B virus markers before immunosuppression or chemotherapy

SocietyWho should be screened?Screening tests
AGAPatients at moderate or high risk of HBVrHBsAg, anti-HBc + HBV DNA in case of positive results
ASCOGroups at heightened risk for chronic HBV infection or if highly immunosuppressive treatment is plannedHBsAg+- anti-HBc in some populations
CDCAll persons receiving cytotoxic or immunosuppressive therapyHBsAg, anti-HBc, and anti-HBs
DGHOGroups at heightened riskHBsAg, anti-HBc + HBV DNA in case of positive results
ECCOAll IBD patients at diagnosisHBsAg, anti-HBc, and anti-HBs + HBV DNA in case of positive results
EASLAll candidates for chemotherapy and immunosuppressionHBsAg, anti-HBc, and anti-HBs +HBV DNA in case of positive results
  • AGA = American Gastroenterological Association; anti-HBc = hepatitis B core antibody; anti-HBs = hepatitis B surface antibody; ASCO = American Society of Clinical Oncology; CDC = Centers for Disease Control and Prevention; DGHO = German Society for Haematology and Medical Oncology; EASL = European Association for the Study of the Liver; ECCO = European Crohn´s and Colitis Organisation; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; HBV DNA = hepatitis B virus DNA; HBVr = hepatitis B reactivation; IBD = inflammatory bowel disease